Is Autolus Therapeutics Stock a Good Investment?
Autolus Therapeutics Investment Advice | AUTL |
- Examine Autolus Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Autolus Therapeutics' leadership team and their track record. Good management can help Autolus Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceutical Products space and any emerging trends that could impact Autolus Therapeutics' business and its evolving consumer preferences.
- Compare Autolus Therapeutics' performance and market position to its competitors. Analyze how Autolus Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Autolus Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Autolus Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Autolus Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Autolus Therapeutics is a good investment.
Sell | Buy |
Strong Buy
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Autolus Therapeutics Stock
Researching Autolus Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 18.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.56. Some equities with similar Price to Book (P/B) outperform the market in the long run. Autolus Therapeutics recorded a loss per share of 1.16. The entity had not issued any dividends in recent years.
To determine if Autolus Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Autolus Therapeutics' research are outlined below:
| Autolus Therapeutics generated a negative expected return over the last 90 days | |
| Autolus Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 1.7 M. Net Loss for the year was (208.38 M) with loss before overhead, payroll, taxes, and interest of (130.86 M). | |
| Autolus Therapeutics currently holds about 216.44 M in cash with (145.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.38. | |
| Over 76.0% of the company shares are held by institutions such as insurance companies |
Autolus Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Autolus Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Autolus Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Autolus Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 785.06 M.Basic technical analysis of Autolus Stock
As of the 22nd of November, Autolus Therapeutics shows the Standard Deviation of 4.71, mean deviation of 3.42, and Risk Adjusted Performance of (0.06). Autolus Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Autolus Therapeutics market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Autolus Therapeutics is priced correctly, providing market reflects its regular price of 2.84 per share. Please also double-check Autolus Therapeutics jensen alpha, which is currently at (0.51) to validate the company can sustain itself at a future point.Autolus Therapeutics' Outstanding Corporate Bonds
Autolus Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Autolus Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Autolus bonds can be classified according to their maturity, which is the date when Autolus Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Autolus Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Autolus Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (0.49) | |||
| Mean Deviation | 3.42 | |||
| Coefficient Of Variation | (1,145) | |||
| Standard Deviation | 4.71 | |||
| Variance | 22.19 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.51) | |||
| Total Risk Alpha | (1.04) | |||
| Treynor Ratio | (0.50) | |||
| Maximum Drawdown | 26.03 | |||
| Value At Risk | (7.83) | |||
| Potential Upside | 6.49 | |||
| Skewness | (0.15) | |||
| Kurtosis | 1.75 |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (0.49) | |||
| Mean Deviation | 3.42 | |||
| Coefficient Of Variation | (1,145) | |||
| Standard Deviation | 4.71 | |||
| Variance | 22.19 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.51) | |||
| Total Risk Alpha | (1.04) | |||
| Treynor Ratio | (0.50) | |||
| Maximum Drawdown | 26.03 | |||
| Value At Risk | (7.83) | |||
| Potential Upside | 6.49 | |||
| Skewness | (0.15) | |||
| Kurtosis | 1.75 |
Consider Autolus Therapeutics' intraday indicators
Autolus Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Autolus Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Autolus Therapeutics time-series forecasting models is one of many Autolus Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Autolus Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Autolus Stock media impact
Far too much social signal, news, headlines, and media speculation about Autolus Therapeutics that are available to investors today. That information is available publicly through Autolus media outlets and privately through word of mouth or via Autolus internal channels. However, regardless of the origin, that massive amount of Autolus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Autolus Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Autolus Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Autolus Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Autolus Therapeutics alpha.
Autolus Therapeutics Corporate Management
| Olivia Manser | Director Relations | Profile | |
| David Brochu | Senior Officer | Profile | |
| Chris Williams | Senior Development | Profile | |
| Robert Dolski | Chief Officer | Profile | |
| Lucinda Crabtree | Chief Officer | Profile | |
| Alexander Swan | Senior Officer | Profile |
Already Invested in Autolus Therapeutics?
The danger of trading Autolus Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Autolus Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Autolus Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Autolus Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Autolus Therapeutics is a strong investment it is important to analyze Autolus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Autolus Therapeutics' future performance. For an informed investment choice regarding Autolus Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Autolus Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.